Abstract: Objective: To evaluate application of Time - by - time oral method for the colon disease patients who use Polyethylene Glycol Electrolytes Powder (II) treatment method in electronic colonoscopy. Methods: 100 patients were invested to join our study from January 2019 to March 2019. They use Polyethylene Glycol Electrolytes Powder (II) treatment method in electronic colonoscopy process. They were randomly assigned to control group (n=50) and intervention group (n=50). In intervention group, the participants receive time - by - time oral method when they use PGEP2. The control group participants use the PGEP2 by the usual way. The collected data include patient characteristics, effective cleanliness index, adverse reaction and drug tolerance, those data from our recording. In research process, we use the special questionnaires which is Boston Bowel Preparation Scale (BBPS). Result: The two different group participants have similar patient characteristics and effective cleanliness in study result from patient characteristics research and BBPS. In addition, the intervention group has lower abdominal distension rate than that of control group in result, it is statistical significance [1 (2% vs 17 (34%), p < 0.001]. In addition, the intervention group patients have better drug tolerance, the result is statistical significance [50 (100%) vs 44 (88%), p=0.035]. Conclusion: the time - by - time oral method is good for reduce the rate of adverse reaction, such as nausea and abdominal distension. Additionally, it can improve the drug tolerance, it shows more patients can take medicine on time in the process of using a drug.Abstract: Objective: To evaluate application of Time - by - time oral method for the colon disease patients who use Polyethylene Glycol Electrolytes Powder (II) treatment method in electronic colonoscopy. Methods: 100 patients were invested to join our study from January 2019 to March 2019. They use Polyethylene Glycol Electrolytes Powder (II) treatment meth...Show More
Abstract: Objective: To analyze sputum culture and drug sensitivity test in patients with severe pneumonia who have abnormal Klebsiella pneumoniae. Methods: 216 patients who were diagnosed as severe pneumonia were invested to join our study. All participants received the sputum culture test before they receive the treatment, their inspection time was from January 2016 to December 2016. we use different antibiotic discs to test the drug resistance in test medium, it can test the effects of several major antibiotics on Klebsiella pneumoniae. Our research is focus on the information about Drug resistance for Klebsiella pneumoniae. The collection information includes patient characteristics, Klebsiella pneumoniae source medical department and drug resistance of different antibiotics for Klebsiella pneumoniae. Result: Most Klebsiella pneumoniae sample from ICU (29.6%), Respiratory ward (31.0%), Neurological ward (19.0%) and Cardiovascular ward (43.7%). The klebsiella pneumoniae sample of another source are less than 5% in our research result. Some antibiotics have good influence to Klebsiella pneumoniae, that include cefoperazone/sulbactam, Meropenem and Ciprofloxacin (8.9% & 10.9% & 12.9%). However, the result indicate the Aztreonam has strong drug resistance for Klebsiella pneumoniae, it has 66 out of 99 (66.66%) number of resistant. Conclusion: The cefoperazone/sulbactam, Meropenem and Ciprofloxacin have good influence to improve klebsiella pneumoniae situation on patients with severe pneumonia. Additionally, some medical departments have more patients who severe pneumonia caused by klebsiella pneumoniae, such as ICU, Respiratory ward, Neurological ward and Cardiovascular ward.Abstract: Objective: To analyze sputum culture and drug sensitivity test in patients with severe pneumonia who have abnormal Klebsiella pneumoniae. Methods: 216 patients who were diagnosed as severe pneumonia were invested to join our study. All participants received the sputum culture test before they receive the treatment, their inspection time was from Ja...Show More
